Pharsight

1. Cutivate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7300669	FOUGERA PHARMS	Fluticasone lotion having improved vasoconstrictor activity	Oct, 2019 (4 years ago)

Drug Exclusivity	Drug Exclusivity Expiration
New Patient Population(NPP)	Jan 16, 2018

Market Authorisation Date: 31 March, 2005

Treatment: Relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients one year of age or older

Dosage: LOTION;TOPICAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0005	28 Jul, 2008	1	02 May, 2011	20 Oct, 2019	Eligible

Strength	Dosage	Availability
0.05% Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	LOTION;TOPICAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5639738	FOUGERA PHARMS	Treatment of basal cell carcinoma and actinic keratosis employing hyaluronic acid and NSAIDs	Jun, 2014 (9 years ago)
US5929048	FOUGERA PHARMS	Treatment of conditions and disease	Jun, 2014 (9 years ago)
US5852002	FOUGERA PHARMS	Treatment of conditions and disease	Jun, 2014 (9 years ago)
US5985850	FOUGERA PHARMS	Compositions comprising hyaluronic acid and drugs	Aug, 2015 (8 years ago)
US5792753	FOUGERA PHARMS	Compositions comprising hyaluronic acid and prostaglandin-synthesis-inhibiting drugs	Aug, 2015 (8 years ago)
US5914322	FOUGERA PHARMS	Treatment of disease and conditions	Aug, 2015 (8 years ago)

Market Authorisation Date: 16 October, 2000

Treatment: Treatment of actinic keratoses

Dosage: GEL;TOPICAL